|Status||‒ ODD for treatment of chronic myeloid leukemia on March 17th, 2022.
‒ NDA receipt on September 23th, 2022.
‒ ODD for treatment of acute lymphoblastic leukemia on November 3rd, 2022.
‒ CRL on April 27th, 2023. Handa will supplement deficiencies and submit to FDA ASAP.
|Product Advantages||Handa is utilizing its ONCORE™ technology to develop improved versions of Oncology drug for reducing the risk associated with sever side effect.。|
|Potential Market||According to the data in 2021 annual report of the brand company, the total sales of the brand drug were US$2.117 billion (US$1.297 billion in the U.S. and US$820 million rest of world).|